DxTerity

DxTerity is a private, commercial-stage diagnostics company leveraging RNA expression profiling to advance precision medicine in autoimmune diseases. Its core technology, the Modular Immune Profile (MIP), analyzes immune-related gene expression from a simple at-home blood sample to monitor disease activity and treatment response. The company has validated its platform through multiple clinical studies (LIFT, EMPOWER, ELEVATE) and collaborates with research institutions and pharma partners. DxTerity operates on a diagnostics business model, generating early revenue from test kits and research services while aiming to secure broader insurance reimbursement.

Modular Immune Profile (MIP) - An RNA-based gene expression profiling platform that uses a small blood sample to measure activity of immune system pathways, such as Type I Interferon, to monitor autoimmune disease status and treatment response.

DxTerity competes in the autoimmune diagnostics space, which includes companies developing multi-analyte assays, digital biomarkers, and traditional lab tests. Its primary differentiation is the focus on decentralized, at-home RNA profiling for longitudinal immune system monitoring, a niche with few established players. Competition may come from large reference labs expanding into genomic testing and other startups exploring liquid biopsy or transcriptomic signatures for autoimmunity.